Infensa Bioscience
Infensa Bioscience is dedicated to developing life-saving therapies targeting the world’s leading causes of death—heart attack and stroke. Their mission is to create game-changing drugs to reduce mortality and morbidity from cardiovascular diseases, with a focus on preventative treatments that protect cells from oxygen deprivation damage. The company emphasizes visionary thinking, rigorous science, world-class talent, adaptability, and unwavering conviction to transform lives globally.
Industries
Nr. of Employees
small (1-50)
Infensa Bioscience
Translational Research Institute, 37 Kent St, Woolloongabba QLD 4102
Products
Cardioprotective drug candidate targeting ASIC1a
A peptide-derived therapeutic candidate that inhibits ASIC1a to reduce ischemia-induced cell death in heart attack, stroke and to improve donor heart preservation; advanced through preclinical efficacy studies with plans for clinical development.
Cardioprotective drug candidate targeting ASIC1a
A peptide-derived therapeutic candidate that inhibits ASIC1a to reduce ischemia-induced cell death in heart attack, stroke and to improve donor heart preservation; advanced through preclinical efficacy studies with plans for clinical development.
Services
Collaborative services to advance discovery candidates through preclinical validation, CMC planning and preparation for clinical translation.
Collaborative services to advance discovery candidates through preclinical validation, CMC planning and preparation for clinical translation.
Expertise Areas
- Cardioprotective drug discovery
- Peptide chemistry and optimisation
- Preclinical cardiovascular models (myocardial infarction, transplantation)
- Stem-cell-based cardiac disease modelling (iPSC)
Key Technologies
- Peptide synthesis (cyclic peptides, disulfide-rich toxins)
- Venom-derived bioactive peptide discovery
- ASIC1a-targeted pharmacology
- In vivo myocardial infarction and transplantation models